7 α-methyl-19-nortestosterone vs. testosterone implants for hypogonadal osteoporosis: A preclinical study in the aged male orchidectomized rat model

International Journal of Andrology

Volumn 34, Issue 6 PART 2, 2011, Pages

  Sinnesael, M ^a   Callewaert, F ^a   Morreels, M ^a   Kumar, N ^b   Sitruk Ware, R ^b   van Proeyen, K ^a   Hespel, P ^a   Boonen, S ^a   Claessens, F ^a   Vanderschueren, D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b POPULATION COUNCIL   (United States)

Author keywords

7 methyl 19 nortestosterone; Bone; Fat; Hypogonadal osteoporosis; Muscle; Testosterone

Indexed keywords

TESTOSTERONE; TRESTOLONE;

ANDROGEN THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SYNTHESIS; HYPOGONADISM; LEAN BODY WEIGHT; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; ORGAN WEIGHT; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ANIMALS; DRUG IMPLANTS; MALE; MODELS, ANIMAL; NANDROLONE; ORCHIECTOMY; OSTEOPOROSIS; RATS; TESTOSTERONE;

EID: 81455131691     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2011.01198.x     Document Type: Article

References (43)

1. Anderson RA, Wallace AM, Sattar N, Kumar N & Sundaram K. (2003) Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 88, 2784-2793.
2. Axell AM, MacLean HE, Plant DR, Harcourt LJ, Davis JA, Jimenez M, Handelsman DJ, Lynch GS & Zajac JD. (2006) Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice. Am J Physiol Endocrinol Metab 291, E506-E516.
3. Behre HM, Kliesch S, Leifke E, Link TM & Nieschlag E. (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82, 2386-2390.
4. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ & Casaburi R. (1997) Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82, 407-413.
5. Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A, van Lenthe GH et al. (2009) Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J 23, 232-240.
6. Callewaert F, Boonen S & Vanderschueren D. (2010a) Sex steroids and the male skeleton: a tale of two hormones. Trends Endocrin Met 21, 89-95.
7. Callewaert F, Venken K, Kopchick J, Torcasio A, van Lenthe GH, Boonen S & Vanderschueren D. (2010b) Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-I: Evidence from pubertal mouse models. J Bone Miner Res 25, 617-626.
8. Chambon C, Duteil D, Vignaud A, Ferry A, Messaddeq N, Malivindi R, Kato S, Chambon P & Metzger D. (2010) Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci USA 107, 14327-14332.
9. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F et al. (2003) A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 88, 5232-5239.
10. Erben RG, Eberle J, Stahr K & Goldberg M. (2000) Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 15, 1085-1098.
11. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI & Crowley WF Jr. (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106, 354-361.
12. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV & Crowley WF Jr. (1989) Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69, 776-783.
13. Finkelstein JS, Neer RM, Biller BM, Crawford JD & Klibanski A. (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326, 600-604.
14. Holmang A, Svedberg J, Jennische E & Bjorntorp P. (1990) Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 259, E555-E560.
15. Kalu DN. (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15, 175-191.
16. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ & Klibanski A. (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81, 4358-4365.
17. Khosla S & Riggs BL. (2005) Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 34, 1015-1030. xi.
18. Kumar N, Didolkar AK, Ladd A, Thau R, Monder C, Bardin CW & Sundaram K. (1990) Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. J Steroid Biochem Mol Biol 37, 587-591.
19. Kumar N, Didolkar AK, Monder C, Bardin CW & Sundaram K. (1992) The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 130, 3677-3683.
20. Kumar N, Crozat A, Li F, Catterall JF, Bardin CW & Sundaram K. (1999) 7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens. J Steroid Biochem Mol Biol 71, 213-222.
21. Meier C, Seibel MJ & Handelsman DJ. (2010) Testicular dysfunction. In: Osteoporosis in Men: The Effects of Gender on Skeletal Health (eds E Orwoll, JP Bilezikian & D Vanderschueren), pp. 423-435. Academic Press, San Diego.
22. Noe G, Suvisaari J, Martin C, Moo-Young AJ, Sundaram K, Saleh SI, Quintero E, Croxatto HB & Lahteenmaki P. (1999) Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum Reprod 14, 2200-2206.
23. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, Vanden Bosch A, Verhoeven G, Hespel P & Vanderschueren D. (2009) Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 150, 3558-3566.
24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM & Recker RR. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2, 595-610.
25. Pette D & Staron RS. (1997) Mammalian skeletal muscle fiber type transitions. Int Rev Cytol 170, 143-223.
26. Prasad PV, Arumugam R, Willman M, Ge RS, Sitruk-Ware R & Kumar N. (2009) Distribution, metabolism and excretion of a synthetic androgen 7alpha-methyl-19-nortestosterone, a potential male-contraceptive. Steroids 74, 121-131.
27. Reim NS, Breig B, Stahr K, Eberle J, Hoeflich A, Wolf E & Erben RG. (2008) Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J Bone Miner Res 23, 694-704.
28. Resko JA, Feder HH & Goy RW. (1968) Androgen concentrations in plasma and testis of developing rats. J Endocrinol 40, 485-491.
29. Riggs BL & Parfitt AM. (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20, 177-184.
30. Seeman E. (2003) Periosteal bone formation - a neglected determinant of bone strength. N Engl J Med 349, 320-323.
31. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R & Bhasin S. (2002) Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 283, E154-E164.
32. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85, 2670-2677.
33. Turner RT, Wakley GK & Hannon KS. (1990) Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 8, 612-617.
34. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R & Vanderschueren D. (2002) Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 17, 2080-2086.
35. Vanderschueren D, Jans I, van Herck E, Moermans K, Verhaeghe J & Bouillon R. (1994) Time-related increase of biochemical markers of bone turnover in androgen-deficient male rats. Bone Miner 26, 123-131.
36. Vanderschueren D, Vandenput L, Boonen S, Van Herck E, Swinnen JV & Bouillon R. (2000) An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology 141, 1642-1647.
37. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R & Ohlsson C. (2004) Androgens and bone. Endocr Rev 25, 389-425.
38. Venken K, Boonen S, Van Herck E, Vandenput L, Kumar N, Sitruk-Ware R, Sundaram K, Bouillon R & Vanderschueren D. (2005) Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone 36, 663-670.
39. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, Verhoeven G & Vanderschueren D. (2006) Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 21, 576-585.
40. Verhaeghe J, Van Herck E, Van Bree R, Van Assche FA & Bouillon R. (1989) Osteocalcin during the reproductive cycle in normal and diabetic rats. J Endocrinol 120, 143-151.
41. Verhaeghe J, van Herck E, Visser WJ, Suiker AM, Thomasset M, Einhorn TA, Faierman E & Bouillon R. (1990) Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 39, 477-482.
42. Wallenius RW, Hibbs JW & Hershberger TV. (1971) Use of bioassay techniques with rats to measure the antithyrotoxic factor in roughages and other materials. J Nutr 101, 621-628.
43. Wang NG, Sundaram K, Pavlou S, Rivier J, Vale W & Bardin CW. (1983) Mice are insensitive to the antitesticular effects of luteinizing hormone-releasing hormone agonists. Endocrinology 112, 331-335.